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ABSTRACT
Seventeen years after the sequencing of the human
genome, the human proteome is still under revision.
One in eight of the 22 210 coding genes listed by the
Ensembl/GENCODE, RefSeq and UniProtKB refer-
ence databases are annotated differently across the
three sets. We have carried out an in-depth investiga-
tion on the 2764 genes classified as coding by one or
more sets of manual curators and not coding by oth-
ers. Data from large-scale genetic variation analyses
suggests that most are not under protein-like puri-
fying selection and so are unlikely to code for func-
tional proteins. A further 1470 genes annotated as
coding in all three reference sets have characteristics
that are typical of non-coding genes or pseudogenes.
These potential non-coding genes also appear to be
undergoing neutral evolution and have considerably
less supporting transcript and protein evidence than
other coding genes. We believe that the three refer-
ence databases currently overestimate the number
of human coding genes by at least 2000, complicat-
ing and adding noise to large-scale biomedical ex-
periments. Determining which potential non-coding
genes do not code for proteins is a difficult but vitally
important task since the human reference proteome
is a fundamental pillar of most basic research and
supports almost all large-scale biomedical projects.
INTRODUCTION
Before the human genome was sequenced, most researchers
estimated that human protein coding gene numbers would
be between 25 000 and 40 000 (1), with some estimates closer
to 100 000 genes (2,3). However, the accumulation of exper-
imental data has progressively brought this estimate down.
The ‘finished’ version of the human genome revised the es-
timates to between 20 000 and 25 000 coding genes (4).
The gradual downward trend of the human protein gene
count has been mirrored in the reference human gene set.
The annotation of human coding genes began with the En-
sembl project (5) and the initial release included more than
24 000 coding genes. This number soon decreased to 22 000
as the genome assembly improved and automatic predic-
tions were refined (6). Until recently there were still gene
loci in the reference set defined as coding based on the ini-
tial automatic predictions, and a number of these had little
support as coding genes beyond their initial prediction. Af-
ter the merge with the GENCODE manual annotations (7)
in 2009, 1004 poorly supported automatic annotation mod-
els were removed from the Ensembl annotation set.
These refinements and intensive manual annota-
tion have brought the number of annotated protein
coding genes down to slightly over 20 000 genes
in the Ensembl/GENCODE (7,8) reference, and in-
deed the three maintained manual reference databases,
Ensembl/GENCODE, RefSeq (9) and UniProtKB (10),
have converged on similar numbers of protein coding genes
[f1000research: doi: 10.12688/f1000research.11119.1], a
number that is in line with the prediction by Clamp et al.
using evolutionary comparisons (11).
However, the human gene sets are in certain state of flux
with coding genes being added and reclassified with each
new release, and it is important to note that these 20 000
plus coding genes are not the same in each database. Indeed,
as we show in this paper, the number of annotated coding
genes in the union of the three reference sets exceeds 22 000.
The task of manually inspecting >20 000 annotated cod-
ing genes is enormous and the process has taken many
years (7). Manual annotators have to accomplish two dif-
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ficult tasks, detecting the remaining hard-to-find coding
genes, and separating bona fide coding genes from misan-
notated pseudogenes and non-coding genes. Curators de-
termine the status of the gene models based on transcript
(ESTs and mRNAs) and protein data (from the main pro-
tein databases) available for each gene (12). Protein-coding
potential depends first on whether an open reading frame
(ORF) can be defined. However, the definition of ORFs is
complicated by the fact that many noncoding transcripts
may contain long ORFs by chance, particularly in GC-
rich regions (11). In order to get round this problem, an-
notators also require some sort of protein evidence, such
as whether the locus has sequence similarity to orthologues
from other species, whether the resulting gene product con-
tains Pfam functional domains (13), or whether experimen-
tal data is available from published papers, large-scale inter-
action studies (14) or mass spectrometry experiments (15).
Genes and transcripts may change their status between
releases as annotators adjust the annotation to the available
evidence. A gene’s status is updated based on the available
evidence and this evidence can change over time. For ex-
ample GENCODE manual annotators recently decided to
reclassify as non-coding approximately 200 ‘orphan’ pro-
tein coding genes [GENCODE blog, https://gencodegenes.
wordpress.com, April 2018]. Most of these genes were early
in silico predictions.
A number of studies have put an estimation on the num-
ber of human coding genes, including several that have es-
timated the number to be close to or below 20 000 (11,16–
18). Two of the more comprehensive studies into the coding
complement of the human genome, Clamp et al. (11) and
Church et al. (17), were carried out before GENCODE and
other groups began the systematic manual reannotation of
the genes in the human gene set. Both analyses assumed that
most novel genes, defined as genes that arose from scratch
in the primate lineage, are not protein coding. According
to the Clamp analysis, the vast majority of novel ORFs did
not have evolutionary conservation and had features that
resembled non-coding RNA rather than coding genes. After
discarding these orphan DNA sequences, as well as genes
that appeared to be transposons, pseudogenes, and other
miscellaneous artefacts, the authors ended up with a gene
count of 20 500, roughly 4000 fewer than were annotated
at that time. Church et al. carried out a comparison be-
tween the human and the mouse genomes and found that
there were very few truly novel human genes, and that al-
most all protein-coding genes gained in the mammalian lin-
eage were generated from whole gene duplications. They es-
timated that the number of protein coding genes was <20
000.
Many of the genes tagged as non-coding in these two
analyses have since been removed from the reference set af-
ter manual annotation, though a number of genes identi-
fied in both studies as orphans or pseudogenes are never-
theless still annotated as protein coding, including the pre-
dicted pseudogenes DHFRL1, which has experimental evi-
dence for a protein, and HIGD2B, which does not.
In 2014, we predicted that the human genome was likely
to have just 19 000 protein coding genes based on the iden-
tification of 2001 ‘potential non-coding’ genes (18). GEN-
CODE manual annotators have since withdrawn or reclas-
sified almost half of these genes from the human refer-
ence set. Most recently Southan [f1000research: doi: 10.
12688/f1000research.11119.1] contrasted gene numbers in
the three manually annotated reference sets with those of
the HUGO Gene Nomenclature Committee [HGNC, (19)],
noting the differences in coding gene counts and showing
that UniProtKB proteins missing in RefSeq and Ensembl
were enriched for elements classified by HGNC as endoge-
nous retrovirus, long non-coding RNA or pseudogene.
Here, we expand our previous analysis to incorpo-
rate an analysis of the RefSeq and UniProtKB pro-
teomes. We find that these two references databases and
Ensembl/GENCODE annotate 22 210 genes as coding but
only agree on 86% of the genes they annotate. In order to
determine whether all 22 210 genes will code for proteins we
contrasted the experimental evidence for genes annotated as
coding in all three reference sets with those that are classi-
fied differently.
MATERIALS AND METHODS
Comparison of Ensembl/GENCODE, RefSeq and UniPro-
tKB gene sets
We merged the coding genes in the three main versions of
the reference human proteome, the Ensembl/GENCODE
reference set (GENCODE v24, which is the equivalent of
Ensembl 83), the RefSeq gene set (RefSeq 107) and the
UniProtKB proteome (UniProtKB June 2016).
The UniProtKB reference proteome contained more
than 70 612 SwissProt (reviewed) and TrEMBL (non-
reviewed) entries. In order to compare UniProtKB with
RefSeq and Ensembl/GENCODE, we merged these entries
where possible by gene name. In UniProtKB genes can have
more than one entry and UniProtKB entries may have more
than one gene. After the initial merge the many orphan tran-
scripts were merged first by their associated Ensembl identi-
fier and then by hand where possible. This set of UniProtKB
genes were then merged with the RefSeq and Ensembl genes
using Ensembl’s BioMart, UniProtKB’s mapping tools and
the HGNC gene names provided by the three reference sets.
We carried out a painstaking manual reannotation of the
more than 2700 genes where HGNC gene names, BioMart
and UniProtKB correspondences did not agree.
Finally, for the 2764 genes not classified as coding in all
the three reference databases we manually cross-referenced
their status in the reference sets in which they were not an-
notated as coding.
Possible non-coding features
We have shown that a number of protein features, such as
gene family age and cross-species conservation, are corre-
lated with the detection of peptides in mass spectrometry
experiments (18). These features can also be used to predict
whether peptides will be detected in proteomics experiments
and to flag protein-coding genes as potentially non-coding.
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UniProtKB uncertain, predicted, homology and missing evi-
dence codes
Protein evidence codes are taken from the UniProtKB
database. UniProtKB carries out manual annotation of pro-
teins and human proteins in particular are well annotated
and a large majority are annotated with the highest evidence
score ‘protein evidence’. The other four evidence codes in
decreasing order are: ‘Transcript evidence’, ‘Homology’,
‘Predicted’ and ‘Uncertain’.
Where there was more than one UniProtKB entry associ-
ated to an Ensembl/GENCODE gene we chose the UniPro-
tKB entry with the highest ranked evidence to represent
the gene. Genes annotated with ‘Homology’, ‘Predicted’ or
‘Uncertain’ evidence, and those genes for which we could
not detect any evidence code at all, had very little evidence
of protein expression; the four features between them cov-
ered 1599 genes and we found peptide evidence for 52.
UniProtKB cautions
UniProtKB appends cautions to many of their protein en-
tries. Several of these cast doubt on whether they are ex-
pressed as proteins. We did not select all UniProtKB cau-
tions, just those that suggested that the gene might be non-
coding, non-functional or a pseudogene. The two most
common cautions were: ‘Product of a dubious gene predic-
tion’, ‘Could be the product of a pseudogene’. There were
86 genes tagged with these cautions. We found peptide evi-
dence for just three of these genes.
GENCODE
We took the translated GENCODE sequences as the coding
gene set. The 20,266 genes in this set included not just pro-
tein coding genes, but also immunoglobulin receptors, non-
sense mediated decay (NMD) transcripts and polymorphic
pseudogenes. 13 148 of the coding genes are also annotated
with non-coding transcripts, but these were not analysed.
Polymorphic pseudogenes
Polymorphic pseudogenes are loci that are pseudogenes in
the reference genome that are intact in other individuals,
and may represent coding genes that are undergoing a pro-
cess of pseudogenization. There are 58 polymorphic pseu-
dogenes in the reference gene set, of which 43 are olfactory
receptors. It is particularly difficult to determine whether
olfactory receptors are pseudogenes or code for functional
proteins (20). We find peptide evidence for two of these
polymorphic pseudogenes, GBA3 and PNLIPRP2. Unlike
most genes annotated with the polymorphic pseudogene
tag, these two genes were annotated with both coding and
polymorphic pseudogene transcripts.
Nonsense-mediated decay genes
A number of genes in the reference gene set only have NMD
and non-coding transcripts. There were 204 genes anno-
tated just with NMD and/or non-coding transcripts in the
GENCODE v24 reference set. As might be expected, we did
not find peptides for any of these genes.
Read-through transcripts
Read-through genes are genes in which all coding or NMD
transcripts are tagged as read-through transcripts. There are
also genes that have a mix of read-through and coding tran-
scripts, though these are gradually being cleaned up. Read-
through transcripts usually occur when a transcript skips
the 3′ exon and reads through to exons from the neighbour-
ing gene (which is usually coding but may be non-coding
or pseudogene too). If translated, read-through transcripts
would produce fusion proteins.
Read-through variants are annotated as part of the hu-
man coding gene set for technical reasons. While it is possi-
ble that the splicing together of two neighbouring genes is
one way for proteins to gain new domains (21), it appears
that very few of these read-through transcripts produce pro-
teins at detectable levels. While we found peptide evidence
for one of these genes (IQCJ-SCHIP1), there is enough ev-
idence to suggest that it may actually be a single gene rather
than two separate genes with read-through transcripts
Because read-through transcripts and proteins overlap
with transcripts and proteins from known coding genes,
these transcripts introduce a number of technical prob-
lems to genome-scale analysis. For example we had to map
the spectra from the MS analyses to the GENCODE v24
database twice, once including the read-through proteins
and once excluding them.
The numbers of read-through genes in the coding gene set
is ever increasing. There were 470 read-through genes anno-
tated either by GENCODE or in the Ensembl description.
Ensembl
Pseudogenes, non-functional genes, non-coding genes,
antisense/opposite strand genes, miscellaneous RNA. We
manually curated genes with tags from the Ensembl gene
descriptions. Genes that were annotated as ‘pseudogene’,
‘read-through’, ‘non-coding’, ‘non-functional’, ‘antisense’,
‘opposite strand’ and ‘long non-coding RNA’ were tagged
as potentially non-coding. There were 131 genes described
as pseudogenes by Ensembl, 70 were olfactory receptors.
We found peptide evidence for 4 of these genes. Another
93 genes were described as ‘non-functional’, ‘antisense’ or
‘opposite strand’. We found peptide evidence for 6 of these
genes. Finally 6 genes were described as ‘non-coding’ or
‘long non-coding RNA’. We found peptides for three of
these genes.
Primate gene family. These were genes from families that
evolved in the primate lineage according to our analysis of
data from Ensembl Compara (22). The primate lineage was
here defined as all strata more recent than the boroeuthe-
ria class. Gene birth dating was carried out used the phy-
logenetic reconstructions of Ensembl Compara v84. We es-
timated a gene family age and an individual gene age for
all coding genes annotated in GENCODE v24. The anal-
ysis was identical to that carried out in the previous pa-
per (18), which itself was based on earlier study of gene
ages (23) and is detailed below. Ensembl Compara v84 is
constructed from genes from 70 different species; here we
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ancestors of Homo sapiens and that had at least 5× cov-
erage. Inconsistencies between gene trees and species phy-
logeny have been described for the Euarchontoglires phy-
lostratum (24,25), so this was collapsed into the Euthe-
rian level. Human coding genes were classified in the fol-
lowing age classes: Fungi/Metazoa, Bilateria, Chordata,
Vertebrata, Euteleostomi, Sarcopterygii, Tetrapoda, Am-
niota, Mammalia, Theria, Eutheria, Boreoeutheria, Pri-
mates, Simiiformes, Catarrhini, Hominoidea, Hominidae,
HomoPanGorilla and H. sapiens. In the analysis, all classes
from Boreoeutheria to H. sapiens formed the ‘Primate’
class. The Sarcopterygii class was later clustered with Eu-
teleostomi class because it contained few genes.
Compara classifies speciation and duplication nodes in
family trees by the phylogenetic level in which the event took
place (26) and our pipeline uses this information to define
the gene family age and the gene age of each coding gene.
Gene family age is the phylostratum at the root of the family
tree (the earliest common ancestor that has a member of the
gene family) while gene age is the phylostratum in which the
genomic event leading to an extant gene takes place. For
singleton genes the family gene age is always the same as
the gene age, for duplicated genes the gene age represents
the species in which the last duplication took place. Only
duplication events with a consistency score (27) >0.3 were
considered in the gene age analysis. Nodes with zero scores
were trimmed out of the analysis. Duplication nodes with
consistencies between 0 and 0.3 were labelled as ‘unclear’
and gene age was not assigned.
To our surprise we found more primate family genes in
this study (700) than in our previous study (563). We found
protein evidence for just 27 primate family genes.
Curiously there are sixteen coding genes that Compara
tags as novel (non-duplicated) human genes in GENCODE
v24. All are single exon genes predicted by Ensembl auto-
matic prediction programs (e.g. see Supplementary Figure
S1). None of these novel human genes have their coding sta-
tus supported in any other reference set or any by peptide
or antibody evidence.
PhyloCSF Score. We used exon-based PhyloCSF scores
(27) to represent a measure of conservation for each gene.
PhyloCSF was run using the 58 mammals parameters and
the ‘mle’ and ‘bls’ option on the coding portion of each
exon, trimmed to codon boundaries and excluding the fi-
nal stop codon. Alignments were extracted from the 100-
vertebrate MULTIZ hg38 alignment, with species restricted
to the 58 placental mammals.
The conservation score was the PhyloCSF score of the
highest scoring exon, counting only exons at least 42 bases
in length and for which the relative branch length of the lo-
cal alignment reported by PhyloCSF’s ‘bls’ option was at
least 0.1, since PhyloCSF scores are unreliable if there is in-
sufficient branch length. Genes having no exons satisfying
these conditions were flagged as having exons that were too
short or with too few relatives to return a PhyloCSF score.
Genes with a maximum PhyloCSF exon score of less than
−16 or genes that had a relative branch length of less than
0.1 were flagged as having a poor PhyloCSF score. We found
peptide evidence in PeptideAtlas for 28 of the 453 genes with
poor branch length and 2 of the 132 genes with a maximum
PhyloCSF exon score of less than −16.
APPRIS. All Ensembl genes are annotated with protein
data in the APPRIS database (28). APPRIS annotates
the following protein-based features: homology to proteins
with known structure is mapped onto variants using HH-
search (29); functionally important residues and protein
functional domain mapping comes from firestar (30) and
pfamscan (31); trans-membrane helices are mapped using
three separate trans-membrane predictors (32–34) and sig-
nal peptides are predicted by SignalP (35). A module of AP-
PRIS calculates a measure of conservation by mapping ver-
tebrate orthologues present in the protein databases. While
APPRIS calculates features for all annotated coding vari-
ants, we took the mapping from the principal isoforms for
each gene.
Protein features were calculated for all genes. Genes that
did not have functional information, structural information
or conservation in formation were tagged as potential non-
coding when they had a PhyloCSF score below 2. There
were just 17 genes with no protein information but with pep-
tide evidence in our analysis.
Transcript expression from Human Protein Atlas. We
downloaded data from the RNAseq experiments carried
out for the Human Protein Atlas (36). The Human Protein
Atlas RNAseq experiments were carried out on 36 tissues
using Ensembl v83 (equivalent to GENCODE v24). For
each gene, we counted the number of tissues in which the
expression level was measured to be at least 1 transcript per
million (TPM). Genes were binned by the number of tissues
in which they were detected with at least 1 TPM.
Peptide data from PeptideAtlas. We downloaded all pep-
tides identified in the January 2016 build of the human Pep-
tideAtlas (15), in total 1 166 164 peptides. 880 101 peptides
(75.5%) were semi-tryptic with respect to the GENCODE
v24 human reference set, even though trypsin is used to
cleave the proteins in the vast majority of proteomics ex-
periments. We have previously found that semi-tryptic pep-
tides are considerably less reliable than tryptic peptides (18),
though most of these peptides were by-products of wholly
tryptic peptides.
Including semi-tryptic peptides would have identified 711
more genes, 13.5% of which would have been potential non-
coding genes. Less than 1% of the genes identified with tryp-
tic peptides were potential non-coding genes. There is no
reason why semi-tryptic peptides should identify 10 times
as many potential non-coding genes than tryptic peptides,
so semi-tryptic peptides were excluded on the grounds of
accuracy.
We also eliminated peptides shorter than nine residues
and peptides that mapped to more than one gene. Finally,
we eliminated nested peptides; where two peptides had the
same sequence but one was shorter than the other, we elim-
inated the shorter peptide. We mapped the remaining 153
913 peptides to the genes in GENCODE v24. At least two
peptides had to map to each gene in order to identify it.
Obtaining and filtering of CNV maps. Whole genome copy
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five different publications (37–41). In order to homoge-
nize the different maps, we selected autosomal and not pri-
vate CNVs. Additionally, we removed CNVs marked as low
quality from Handsaker et al. (40) and all the variants from
two of the individuals (NA07346 and NA11918) because we
were not confident about their genotype. From the maps in
Zarrei et al., (39) we selected the stringent map that con-
sidered CNVs that appeared in at least two individuals and
in two studies. Homozygous whole gene losses were calcu-
lated for all maps except for Abyzov et al., (41) which did
not specify the copy number of the deletions.
Genetic variation. We compared rates of genetic variation
for genes with potential non-coding features against the
genetic variation rates for likely coding genes using data
from 2504 individuals in phase 3 of the 1000 Genomes
Project (42). We remapped these variants from GRCh37
to GRCh38 using dbSNP v149 (43). Most of the variants
could be mapped from GRCh37 to 38 by using dbSNP iden-
tifiers (rsIDs). The exceptions were 186 854 variants with no
rsID in dbSNP v149, and 256,769 variants for which the ref-
erence base has changed between GRCh37 and GRCh38.
The rest of the variants (99.47%; 84 358 257/84 801 880)
were successfully mapped. When available, ancestral allele
information from the 1000 Genomes Project was used to
translate allele frequencies into derived allele frequencies.
We ran VEP (variant effect predictor.pl, (44)) v84 using
either the Ensembl v84 cache (for Ensembl/GENCODE)
or a cache built locally using gene annotations from Ref-
Seq v107 to predict the effects of variants. We calculated
the percentage of high-impact variants and the ratio of non-
synonymous to synonymous variants for rare and common
allele frequencies. High impact variants were splice accep-
tor, splice donor, stop gain and stop loss variants. Common
alleles were those with an allele frequency higher than 0.005
(equivalent to >25 allele counts in autosomes), while rare
alleles were those with an allele frequency <0.005.
Only variant effects corresponding to the APPRIS princi-
pal isoform (28) of each coding gene were considered. Vari-
ants were considered only for strictly defined protein coding
genes, not for the immunoglobulin and t-cell receptor frag-
ment genes to exclude the possibility of positive selection.
RESULTS
Coding genes in the three main reference sets
We compared the coding genes in the three main versions
of the human proteome, the merged Ensembl/GENCODE
reference set, the RefSeq gene set and the UniProtKB
proteome. The comparison was based on GENCODE
v24 (Ensembl 83), UniProtKB June 2016, and RefSeq
107. RefSeq 107 annotates 20 450 coding genes, and
the Ensembl/GENCODE merge contains 20,266 coding
genes. The UniProtKB proteome is based around proteins
rather than genes. UniProtKB June 2016 proteins mapped
to 21 212 coding genes.
In total the three reference sets annotate 22 210 protein-
coding genes. There are a maximum of 19 446 genes an-
notated as coding in the intersection of the three sets
(Figure 1). This is a maximum because boundaries are
disputed for a small number of genes. There are eight
Figure 1. The overlap between Ensembl/GENCODE, RefSeq and
UniProtKB genes. The number of genes classified as coding in each of
the three reference databases and the intersection between them. The
number of genes in the intersection of A is variable because RefSeq and
Ensembl/GENCODE disagree on gene boundaries for a number of genes.
For three subsets of genes, we show the percentage of coding genes anno-
tated as antisense, pseudogene or read-through in another database.
cases where Ensembl/GENCODE has two genes but Ref-
Seq annotates one gene and sixteen cases where sin-
gle Ensembl/GENCODE genes are annotated as multiple
genes in RefSeq (PTPRQ is three RefSeq coding genes and
only one in Ensembl/GENCODE). If all 24 genes were sin-
gle genes rather than being split, there would be 19 421 cod-
ing genes common to the three reference sets. Beyond the
intersection of the three reference databases, 851 genes are
supported by two of the three reference sets and 1903 genes
are annotated in just one of the three reference sets.
Ensembl/GENCODE has the fewest unique coding
genes (105). This is for technical reasons. Most genes
annotated by Ensembl/GENCODE are automatically in-
cluded in UniProtKB. Given the near automatic transmis-
sion of coding genes between Ensembl/GENCODE and
the UniProtKB proteome, the 690 genes annotated as cod-
ing by Ensembl/GENCODE and UniProtKB might also be
regarded as singleton coding genes.
Almost a quarter of coding genes not present in all three
reference sets are annotated as pseudogenes by manual an-
notators from other databases (Supplementary Table S1)
and this rises to 39% of coding genes annotated in UniPro-
tKB only (Figure 1). Potential ‘antisense’ genes, non-coding
genes on the opposite strand to protein-coding loci, form
the second largest group of differently annotated genes; 17%
of coding genes not annotated in all three sets and 31% of
genes classified as coding in RefSeq only are antisense. More
than 50% of genes that are coding in Ensembl/GENCODE
and UniProtKB but not in RefSeq are read-through genes.
Read-through genes (genes made up entirely of transcripts
that skip the last exon of one coding gene to read through
to exons from the neighbouring gene or pseudogene) are
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Ensembl/GENCODE annotations even though there is lit-
tle indication that they code for proteins.
Each reference set has its own biases and idiosyncrasies.
UniProtKB annotates 26 retroviral genes and a large num-
ber of T-cell receptor and immunoglobulin genes as part of
the human reference proteome and include 84 genes that are
part of alternative loci in the haploid assembly. RefSeq an-
notates 44 genes as sense overlapping (i.e. the locus of the
gene overlaps with a known protein coding gene in the same
sense), while Ensembl/GENCODE has 41 genes that are
exact duplicates of annotated coding genes due to techni-
cal problems with the merge between GENCODE and En-
sembl (Supplementary Table S1).
Are there 22 210 coding genes in the human genome?
There is a remarkable discrepancy between the number of
genes classified as coding by all three reference sets and the
number of genes classified as coding by at least one of the
individual reference sets; 14.4% more genes are classified as
coding in the union of the three reference sets than in the
intersection. How many of these 2764 extra genes annotated
by just one or two of the reference databases are protein
coding?
UniProtKB annotation
Genes classified as coding solely by UniProtKB are unique
in that they do not come with reference coordinates. In-
deed many UniProtKB proteins are annotated as unplaced
because the annotators do not know where in the genome
the gene is found. However, the UniProtKB database pro-
vides an evidence scale for their manual annotations, rang-
ing from the most reliable (‘supported by protein evidence’)
to the most dubious (‘uncertain’). We used these classifica-
tions to compare genes classified as coding by UniProtKB.
For each gene, we took the protein with the most reliable
evidence as the representative.
The evidence codes of genes classified as coding in the
coding gene subsets (UniProtKB and RefSeq, UniPro-
tKB and Ensembl/GENCODE and solely UniProtKB) are
clearly distinct from those classified as coding in all three
reference databases (Supplementary Figure S2). More than
80% of the genes classified as coding across all three refer-
ence databases are annotated with the highest UniProtKB
evidence score, ‘supported by protein evidence’. Outside of
this intersection the proportion of genes supported by pro-
tein evidence is much smaller; those genes annotated by
UniProtKB only have the next highest level of confirmation
with just 19% of proteins supported by protein evidence,
and three quarters of these are immunoglobulin genes, T-
cell receptors, viral proteins and proteins from alternative
loci that are not in the reference genome-based databases.
By contrast >50% of the coding genes unique to UniPro-
tKB are supported by the ‘uncertain’ evidence code, while
over half the genes classified as coding by UniProtKB and
RefSeq are supported by transcript evidence alone, and
more than two thirds of genes that are classified as coding
by UniProtKB and Ensembl/GENCODE are annotated as
being supported by ‘predicted’ evidence. Genes annotated
as coding in just one or two reference databases clearly have
much weaker evidence in UniProtKB.








No protein features [A] 586 17
Primate gene [C] 700 27
Pseudogene [E] 131 4
Non-functional [E] 74 6
Antisense/Opposite Strand [E] 19 3
Non-coding [E] 6 3
Read-through gene [G] 467 1
Nonsense mediated decay [G] 204 0
Polymorphic pseudogene [G] 56 2
PhyloCSF branch length [M] 453 28
PhyloCSF maximum [M] 132 2
Predicted evidence [U] 853 12
Homology evidence [U] 613 39
No evidence code [U] 101 0
Caution note [U] 86 3
Uncertain evidence [U] 32 1
The abbreviations show the source of each annotation: A – APPRIS, C-
Ensembl Compara, E – Ensembl annotations, G – GENCODE annota-
tions, M - MIT, U – UniProtKB annotations.
Potential non-coding features
In a previous work we flagged 2001 coding genes from the
GENCODE v12 gene set as potentially non-coding (18)
based on a set of features that were more typical of non-
coding genes than coding genes (potential non-coding fea-
tures). These features were all associated with extremely
poor detection rates in mass spectrometry analyses. Man-
ual annotators have since reclassified 908 of these genes as
pseudogenes or non-coding RNA. Since genes annotated as
coding in just one or two reference sets have less evidence in
UniProtKB, it seems logical that many of these genes will
also be enriched potential non-coding features.
Using the Ensembl/GENCODE coding genes we de-
fined a set of potential non-coding features. The features
included the weakest three UniProtKB evidence codes and
manually added caution notes from the UniProtKB man-
ual annotators, read-through, nonsense mediated decay and
polymorphic pseudogenes tags from the GENCODE man-
ual annotation, labels indicating pseudogene or non-coding
gene from the Ensembl database and four measures of con-
servation, poor PhyloCSF (21) maximum score and rela-
tive branch length (which indicates that evolutionary cod-
ing potential within placental mammals is low), absence of
conserved protein structure, function or conservation ac-
cording to the APPRIS (28) database and those genes that
have evolved within the primate clade according to Ensembl
Compara (22).
The 16 potential non-coding features, the numbers of
genes that were tagged with each feature and the number
of these genes that had peptide evidence from large-scale
proteomics analyses are listed in Table 1 and the features
themselves are detailed in the Materials and Methods sec-
tion.
A total of 2278 Ensembl/GENCODE coding genes were
tagged with at least one of the 16 potential non-coding fea-
tures. These genes were labelled as ‘potential non-coding
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as the ‘likely coding gene’ set in this analysis. The corre-
spondence between the potential coding genes tagged in
Ensembl/GENCODE and in GENCODE v12 is shown in
Supplementary Figure S3.
Potential non-coding genes are not distributed evenly
between the intersection of three reference sets and the
Ensembl/GENCODE gene subsets (Ensembl/GENCODE
and UniProtKB, Ensembl/GENCODE and RefSeq, and
Ensembl/GENCODE alone). While there were 1471 poten-
tial non-coding genes in the intersection of the three sets,
this was just 7.6% of the genes. By contrast potential non-
coding genes made up 96.5% of the genes (808 of 837) in the
Ensembl/GENCODE gene subsets (Supplementary Figure
S4).
The fact that almost all the genes outside the intersec-
tion of the three reference sets have potential non-coding
features suggests that many of them may not code for pro-
teins under normal cellular conditions. As a first step to test-
ing this hypothesis we analyzed the experimental expression
of potential non-coding genes using available experimental
transcriptomics, proteomic and antibody binding data and
compared this to likely coding genes.
Transcript evidence
We downloaded RNA expression data from the Human
Protein Atlas. The Human Protein Atlas details RNAseq
experiments carried out on 36 tissues using Ensembl83
(equivalent to GENCODE v24). For each gene we looked at
the maximum expression in any one tissue and counted the
number of tissues in which expression was at least 1 tran-
script per million (TPM). We binned genes by maximum
expression and by number of tissues and compared the tis-
sue distributions of likely coding genes and potential non-
coding genes in both the intersection and subsets of coding
genes annotated in Ensembl/GENCODE, but not in both
other reference sets.
There was considerably more evidence for the expres-
sion of likely coding genes: 73.5% of likely coding genes
had a maximum TPM of 20 or more against just 24.3%
of potential non-coding genes (Figure 2). In fact 52.9%
of potential non-coding genes had a maximum TPM of
fewer than 5. The median expression level for potential non-
coding genes was just 4.1 TPM, compared to 43.4 TPM in
the likely coding set. Potential non-coding genes from the
Ensembl/GENCODE coding subsets have a very similar
distribution to potential non-coding genes from the inter-
section of the three sets. There were too few likely coding
genes in the Ensembl/GENCODE coding subsets (29) to
show in the graphic.
Likely coding genes also have entirely different tissue-
specific characteristics from potential non-coding genes.
While likely coding genes tend to be expressed in detectable
quantities over most tissues (62.7% of these genes are de-
tected in at least 30 tissues), the majority of potential non-
coding genes are found in few tissues (Supplementary Fig-
ure S5). More than two thirds of potential non-coding genes
(66.5%) have detectable expression in five or fewer tissues.
The skewed tissue-distribution of both sets of possible
non-coding genes (Supplementary Figure S5) might suggest
that these genes are more tissue-specific, and it is true that a
Figure 2. Maximum transcript expression of potential non-coding genes
and likely coding genes. The percentage of genes in seven different max-
imum TPM bins. Maximum TPM comes from the 36 tissues of the Hu-
man Protein Atlas RNAseq experiments. Tissue distribution shown for
the likely coding genes (LCG Intersection) as well as potential non-coding
genes annotated by all three reference sets (PNC Intersection) and by just
one or two sets of annotators (PNC Subsets).
higher proportion of potential non-coding genes are olfac-
tory receptors and would be expected to be expressed in lim-
ited tissues. However, potential non-coding genes still have
much lower expression levels even when olfactory recep-
tors are removed (Supplementary Figure S6). Most poten-
tial non-coding genes had a maximum expression of fewer
than 5 TPM, so differences in tissue expression might also
be a reflection of generally low expression levels in which
the 1 TPM threshold is crossed only in few tissues.
Protein expression
We carried out two analyses to identify gene products, an
analysis of the collected peptides from the PeptideAtlas pro-
teomics database and an investigation of the antibody infor-
mation housed in the Human Protein Atlas.
We culled peptides from the PeptideAtlas database (Jan-
uary 2016), which contains 238 402 discriminating tryptic
peptides. We required protein detection to be supported by
two or more distinct uniquely-mapping, non-nested peptide
sequences of at least 9 amino acids as suggested by Human
Proteome Project consortium (45).
We detected at least two non-nested peptides for 13 360 of
the 17 988 likely coding genes (74.3%). By way of contrast
genes with potential non-coding features had extremely low
levels of peptide detection [Table 1]. In total we detected
peptides for just 142 of the 2278 potential non-coding genes
(6.2%). Less than 1% of the genes identified by PeptideAtlas
were potential non-coding genes.
Human Protein Atlas antibodies
The Human Protein Atlas has been developed to val-
idate tissue-specific protein expression. We downloaded
antibody-specific protein expression information from nor-
mal tissues from the Human Protein Atlas (Version 16, Jan-
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identified more than one gene and identifications tagged as
‘uncertain’.
The remaining antibodies detected a higher proportion
of protein expression for the genes in the likely coding set
(9896 of 17 988 genes, 55%) than for the genes in the po-
tential non-coding set (just 79 of the 2278 genes, 3.5%).
Potential non-coding genes that were validated by Human
Protein Atlas antibodies included primate genes STATH
(statherin), HTN3 (histatin-3) and SCT (secretin), all of
which code for secreted proteins.
Genes detected by PeptideAtlas peptides and Human
Protein Atlas antibodies are shown in Supplementary Fig-
ure S7. 8794 genes were detected in both analyses, only 46
of which were potential non-coding genes (0.52%). At the
same time 2101 of the 5681 genes not detected in either anal-
ysis (37%) were potential non-coding genes.
There is quite clearly less evidence for the expression
of potential non-coding genes both at the transcript and
protein level. Chi-squared tests show that expression pat-
terns of potential non-coding genes are significantly differ-
ent from those of likely coding genes in all three sets of ex-
perimental observations.
Potential non-coding genes even have even less protein
evidence than one would expect from the RNAseq levels.
Peptides can be found in PeptideAtlas for 92% of likely cod-
ing genes that have RNAseq expression of at least 1TPM
in all 36 Human Protein Atlas tissues (Figure 3), but the
peptide support falls to just 25% for potential non-coding
genes. A similar pattern can be seen when genes are binned
by maximum TPM across all 36 Human Protein Atlas tis-
sues. Proportionally we found 5–10 times more likely coding
genes than potential non-coding genes (Figure 3) in each
bin. Even in the most widely expressed genes, which we de-
fined those genes that are expressed in at least 10 tissues
with a minimum of 10 TPM, there is still much more peptide
evidence for likely coding genes than potential non-coding
genes. We detected peptides for 85.6% of likely coding genes,
19.4% of potential non-coding genes annotated by all three
reference sets and just 6.1% of potential non-coding genes
annotated in two or fewer sets (Figure 3).
Genetic variation
Human genetic variation can be used to shed light on
whether or not potential non-coding genes code for pro-
teins. The rate of copy number variation and the propor-
tion of damaging high impact variants can provide clues to
the functional relevance of coding (or non-coding) genes.
Because of the effects of purifying selection coding genes
should have substantially lower non-synonymous to syn-
onymous variant ratios than non-coding genes that are mis-
annotated as coding.
Copy number variation
We downloaded genome copy number variations (CNV)
maps from five different publications (37–41). The CNVs
were mapped to the GRCh37 build of the human genome,
so we compared rates of gene gain and loss in the subset
of Ensembl/GENCODE genes that were also annotated
GENCODE v12. We also looked at CNVs in those GEN-
CODE v12 genes that have since been removed from the
Figure 3. The relation between peptides in proteomics experiments and
transcript expression. (A) The percentage of genes for which peptides are
detected in PeptideAtlas across nine different bins. The bins are based on
the number of tissues in which the transcripts are detected with a TPM
of >1 in the Human Protein Atlas RNAseq experiments. (B) The percent-
age of genes for which peptides are detected in PeptideAtlas divided across
seven bins of maximum TPM for each gene taken from the 36 tissues of the
Human Protein Atlas RNAseq experiments. (C) The percentage of genes
for which peptides are detected for those genes that have RNAseq expres-
sion in at least 10 tissues with a TPM of 10 or more. In each case the per-
centage of genes for the likely coding genes (LCG Intersection, blue bars)
as well as potential non-coding genes annotated by all three reference sets
(PNC Intersection, yellow) and by just one or two sets of annotators (PNC
Subsets, green).
coding reference set and reclassified as non-coding, pseu-
dogene or artefact.
The rate of gene loss and homozygous gene loss through
CNVs for each set are shown in Figure 4. Potential non-
coding genes from Ensembl/GENCODE have more than
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Figure 4. Whole gene gains and losses for likely coding and potential non-
coding gene in GENCODE v12. The percentage of genes that have under-
gone gene gain/loss (purple), whole gene gain (orange), whole gene loss
(red) or homozygous gene loss (blue) in at least one of the five different
analyses. Potential non-coding genes present in both GENCODE v12 and
v24 undergo a similar proportion of gene gain and loss to GENCODE v12
genes that have since been reclassified as not coding.
almost five times as much genes loss. The distribution of
CNVs in potential non-coding genes is similar to that of
GENCODE v12 genes that are no longer classified as cod-
ing, though potential non-coding genes have even more ev-
idence of gene loss.
Genetic variation within the human population
The patterns from the CNV study suggest that potential
non-coding genes are under weaker selection than likely
coding genes. To further characterize the strength of selec-
tion we analysed the patterns of genetic variation in the hu-
man population using data from 2504 individuals in phase
3 of the 1000 Genomes Project (42). For the calculation we
separated variants by allele frequency: common alleles were
those with an allele count of more than 25, equivalent to an
allele frequency of 0.005, while rare alleles were those with
an allele count of fewer than 25. Variant effects were de-
termined using the main protein isoform to represent each
GENCODE v24 coding gene (28).
The percentage of high-impact variants and the ratio
of non-synonymous to synonymous variants for rare and
common allele frequencies were calculated using the results
from VEP (44). For the large-scale comparison high impact
variants included splice acceptor, splice donor, stop gain,
stop loss, but not indel variants. This is because indels are
generally validated only with higher allele counts and are
therefore almost always overrepresented in common alleles.
If purifying selection is preventing high impact or mis-
sense substitutions, these variants should be depleted from
higher allele frequencies. Hence, differences in the patterns
of high-impact and missense substitutions between rare and
common alleles can be used to determine whether there is
purifying selection or neutral evolution in large sets of pro-
tein coding genes. We have used this method previously to
show that the majority of alternative exons are not under-
going purifying selection (46,47).
The percentage of high impact variants at rare allele fre-
quencies is 1.88% for likely coding genes and this drops to
0.61% for common alleles. Within the likely coding gene set
Figure 5. Genomic variation in likely coding genes and possible non-
coding genes. Percentage high impact variants (yellow) and non-
synonymous/synonymous ratios (blue) for known coding genes (likely
coding genes with peptide evidence, see text) and for possible non-coding
genes (PNC) from the intersection of the three sets (Intersect) or anno-
tated by two or fewer reference sets (Subsets). Read-through genes were
removed when calculating variants because they always overlap known
coding genes. The darker colours show the values for common variants
and the lighter shades show the values for rare variants. 95% confidence
intervals are shown.
there are genes undergoing positive selection and there may
even be genes that are not functionally important within
this set. When we filter out immune system genes from the
likely coding gene set and calculate high impact variants
just for those genes that we detect peptides for, the differ-
ence is even starker: 1.6% for rare allele frequencies and
just 0.36% for common allele frequencies (Figure 5). Likely
coding genes with peptide support also have a much lower
non-synonymous to synonymous ratio in common alleles,
as would be expected for protein-coding genes evolving un-
der negative selection.
By way of contrast potential non-coding genes annotated
in all three sets have proportionally more high impact vari-
ants (3.72% at rare allele frequencies and 2.16% at common
allele frequencies) and non-synonymous to synonymous ra-
tios (2.33 for rare allele frequencies and 2.03 for common
allele frequencies), and the results for potential non-coding
genes annotated as coding in just one or two sets are similar
(Figure 5). The fact that potential non-coding genes have a
much higher proportion of high impact variants and greater
non-synonymous to synonymous ratios than likely coding
genes, suggests that many potential non-coding genes are
unlikely to code for functionally important proteins.
With the genes annotated in Ensembl/GENCODE and
RefSeq it is possible to generate human population data
for all subsets of genes in Figure 1 with the exception of
those genes annotated as coding only by UniProtKB. The
percentage of high-impact variants and the ratio of non-
synonymous to synonymous variants for these subsets are
shown in Supplementary Figure S8. The contrast between
genes classified as coding in all three reference databases
and those in two or fewer sets is clear. Genes classified as
coding in just one or two sets have much higher rates of
high impact variants than genes classified as coding across
all three databases. There are also no significant differences
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common allele frequencies in any set of genes that are clas-
sified differently across the three reference sets.
The genetic variation for individual potential non-coding
features sheds some light on which of the potential non-
coding genes are more likely to code for functional pro-
teins. With the exception of read-through genes (most read-
through genes are two known coding genes joined together)
all features have genetic variant distributions that are very
different from likely coding genes (Supplementary Figure
S9). Primate genes, genes with ‘predicted’ UniProtKB ev-
idence and genes with poor PhyloCSF scores have much
higher non-synonymous to synonymous ratios and percent-
ages of high impact variants than likely coding genes. How-
ever, the non-synonymous to synonymous ratios are lower
for common allele frequencies and the differences between
rare and common allele frequencies are significant. This
suggests that a certain number of genes in these three cate-
gories may be functionally important protein-coding genes.
By contrast there are no significant differences in non-
synonymous to synonymous ratios between rare and com-
mon allele frequencies for genes tagged with the potential
non-coding features ‘pseudogene’, ‘uncertain’ UniProtKB
evidence and ‘UniProtKB caution’, which suggests that a
large majority of these genes are undergoing neutral evolu-
tion and are not functionally important.
Another subset of genes with high rates of damaging
mutations and little differences between rare and common
allele frequency non-synonymous to synonymous ratios
are those genes populated entirely by automatically pre-
dicted transcript models. There were more than 800 genes
predicted automatically in RefSeq and more than 200 in
Ensembl/GENCODE. In sets of automatically predicted
genes non-synonymous to synonymous ratios are practi-
cally identical for rare and common allele frequencies (Sup-
plementary Figure S10), suggesting that most of these genes
are also subject to neutral evolution.
Genes with high rates of missense variants
Genetic variation data is useful for pinpointing probable
neutral evolution in large cohorts of genes, but the sparse-
ness of the variants means that it is difficult to make con-
clusions about most individual genes. A number of cod-
ing genes do have remarkably high rates of missense and
damaging variants though. We looked at the 15 genes with
the highest proportion of non-synonymous variants (min-
imum 30 common allele variants). Nine were HLA histo-
compatibility antigens (Figure 6), which is not surprising
since these genes are known to have many missense vari-
ants. Two of the other six genes might also be expected
to have higher levels of missense variants because of their
likely function. MICA (MHC class I polypeptide-related se-
quence A) a self-recognising antigen from the major his-
tocompatibility complex class I locus and has more than
50 known alleles, several of which are truncating. Similarly,
BTNL2 (Butyrophilin-like protein 2) is a known polymor-
phic locus bordering the major histocompatibility complex
class II and class III regions.
The remaining four genes (Figure 6) are CRIPAK,
PRAMEF2, PRR21 and OR2T8.
PRAMEF2 and OR2T8 are likely to be pseudogenes; ol-
factory receptors are highly duplicated and many of these
duplications may be pseudogenes, while PRAMEF2 has 22
almost identical paralogues, none of which is supported by
protein evidence. PRR21 (Putative proline-rich protein 21)
is a single exon gene, which was annotated as ‘uncertain’ by
UniProtKB but has since been removed from the UniPro-
tKB proteome. It has an orthologue in chimpanzee, but
little other supporting evidence and no evidence of tran-
script expression. CRIPAK (Cysteine-rich PAK1 inhibitor)
was described in a 2006 paper (48) in which CRIPAK con-
structs appeared to bind and block PAK1 activity. It was
described as having 13 zinc finger domains, but the zinc
finger domains are not real domains, merely degenerate
cysteine-rich repeats (Supplementary Figure S11). Mean-
while CRIPAK is primate-specific and has practically no
cross-species conservation at all, as can be seen from the
partial alignment of the few orthologous sequences that can
be found in UniProtKB (Figure 6). Although transcript ex-
pression is ubiquitous, there is no evidence for its expression
as protein. Curiously it has the same expression pattern as
the upstream coding gene, UVSSA (Supplementary Figure
S11). CRIPAK is highly unlikely to be a coding gene and
has been reclassified by GENCODE annotators.
Annotation of coding genes based on conflicting evidence
Manual annotators determine the status of genes based on
the balance of the available evidence. For most genes, the
available evidence is in agreement and the designation of
coding or non-coding status is fairly straightforward. How-
ever for those genes that might be considered edge cases at
the boundary between coding and non-coding, the evidence
can often be contradictory.
There are a number of genes in the potential non-coding
gene set that are supported by published studies, but that
have little other evidence to support their translation to
protein in normal tissues. One example is CRIPAK (see
above), annotated as coding based on a single published
study. At the other end of the spectrum is ARMS2, a gene
that evolved in the primate clade from an L2 transposon.
Since ARMS2 has been linked to macular degeneration, it
has >200 publications, many of which are association stud-
ies. The exact role of ARMS2 in macular degeneration is
not clear. Experiments carried out with a plasmid-induced
protein show that if ARMS2 were expressed in retinal cells,
it would be secreted via an unconventional route (49).
Ensembl/GENCODE and UniProtKB annotate DLEU1
(deleted in leukaemia 1) as encoding a short protein as well
as 33 non-coding transcripts (Supplementary Figure S12).
RefSeq annotate the DLEU1 as non-coding. DLEU1 was
added to UniProtKB in 1997, and in 2007 it was annotated
as having ‘protein evidence’ because it appeared to inter-
act with other proteins in large-scale protein-protein inter-
action experiments (50). There is little other evidence that
DLEU1 codes for a protein. There is no proper proteomics
evidence, very poor cross species conservation, practically
no conservation of the reading frame (12) and coding ex-
ons of DLEU1 overlap with a SINE (MIRb) element.
While UniProtKB annotators use evidence from large-scale
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Figure 6. Genes with the highest proportion of high impact and non-synonymous variants. In (A), the percentage of high impact variants (yellow) and
non-synonymous/synonymous ratios (blue) for the 15 genes with the highest rate of common non-synonymous variants. Minimum 30 common variants
per gene. The darker colors show the values for common variants and the lighter shades show the values for rare variants. In (B), the alignment between
human CRIPAK gene product and primate homologues annotated as CRIPAK in UniProtKB. There is very little evidence of conservation.
with the evidence code, ‘protein evidence’, evidence from
large-scale protein-protein interaction experiments is not
always sufficient to confirm protein-coding status. Large-
scale interaction experiments construct proteins artificially
and use these artificially generated proteins to see if they
stick to other proteins. Proteins are generally sticky, even
artificial ones, so binding between artificial constructs and
real proteins is possible. While a great many of the detected
in vitro interactions may also take place in vivo, a num-
ber will not. DLEU1 is almost certainly a non-coding gene
rather than a coding gene and will be reclassified as non-
coding by Ensembl/GENCODE manual annotators.
There are many potential non-coding genes annotated
with ‘protein evidence’ because of protein-protein interac-
tion studies. These include DRICH1 (which has a dN/dS
above 1 between human and primates and a higher non-
synonymous/synonymous ratio for common allele frequen-
cies), FAM218A (which has very little evidence of homo-
logues, even in primates), PRR20C (which has a dN/dS
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511P7.5 (which appears to be a pseudogene at the 3′ end
of ZNF755).
Some genes within the likely coding gene set also have
conflicting evidence for their coding capability. Polo-like ki-
nase 5 (PLK5) is detailed in Supplementary Figure S13.
Glycine receptor subunit alpha-4 (GLRA4) is interesting
because it is one of a number of coding genes that have
human-specific stop codons. Glycine receptors are ligand-
gated chloride channels and are highly conserved (chicken
and mouse GLRA4 are 94% identical over all but the first 40
residues). A mutation in the human version of GLRA4 gen-
erates a protein that is truncated 39 amino acids from the
C-terminus of the protein, removing the C-terminal trans-
membrane helix (Figure 7). This would almost certainly
destabilize any pore, and would probably have considerable
effect on the function.
The genetic variation for the four human glycine recep-
tor genes is shown in Figure 7 along with data for GLRA4
from the Exac experiment (51). The family members with
intact structure ( GLRA1, GLRA2 and GLRA3) have no
high impact mutations and the non-synonymous to synony-
mous ratio is higher for rare alleles than for common alle-
lesIn contrast, 3% of common alleles variants in GLRA4
are high impact and the non-synonymous to synonymous
ratios are high for both rare and common alleles. The varia-
tion data suggest that GLRA4 is not under selective pressure
and is likely to be a unitary pseudogene.
The propagation of erroneous annotations
GVQW1 and GVQW2 are short primate-specific genes with
poor conservation (Supplementary Figure S14) that are
classified as coding in all three reference databases, but that
are tagged as potential non-coding in our study. GVQW1
originated from an Alu SINE element, while GVQW2 was
annotated as coding recently. Pfam domains (13) are of-
ten used to help distinguish coding genes from non-coding
genes and both genes seem to have been annotated as cod-
ing based on the presence of the domain GVQW.
Pfam annotators have recently removed the transposon-
derived GVQW domain from the database as part of a re-
vision of Pfam families because they no longer believe it is
a true protein family. Unfortunately, when domains are re-
moved from Pfam, there are no mechanisms to revise genes
that were validated as coding based on these Pfam domains.
The now defunct domain seems to have been instrumen-
tal in the prediction of 1178 novel human coding genes
by the CHESS database [BioRxiv: https://doi.org/10.1101/
332825]. These novel predictions were based on RNAseq
evidence and similarity to known proteins. More than half
of these novel genes were similar to one of just nine UniPro-
tKB proteins (eight human and one chimp). The alignment
of the nine proteins (Supplementary Figure S15) shows that
they are all closely related.
Two of these proteins came from GVQW1 and GVQW2.
Although GVQW1 and GVQW2 are in the process of be-
ing reclassified by GENCODE, they are still present in
the UniProtKB and RefSeq reference sets. GVQW1 and
GVQW2 are transposon-based, so it is reasonable to assume
that all nine sequences are derived from Alu sequences (in-
deed isoforms from both C16orf89 and C9orf85 are among
Figure 7. GLRA4 loss of trans-membrane helix and genetic variation. (A)
The cryo-EM structure of the GLRA1 kinase domain from Danio rerio
(PDB code: 3JAD), which is 80% sequence identical to human GLRA4.
In GLRA4, the premature stop codon would lead to the loss of the dark
orange trans-membrane helices in the figure (one of which is marked with
a red arrow). From the point of view of the pore, this would mean the
loss of five of the twenty helices, albeit the helices which are furthest
away from the inside of the pore. This would almost certainly destabi-
lize the pore, and would probably have considerable effect on the func-
tion. It would also leave the C-terminals of the protein on the cytoplas-
mic side instead of the extra-cellular side. (B) The percentage of high im-
pact variants (yellow) and non-synonymous/synonymous ratios (blue) for
the GLRA gene family. The percentage of high impact variants and non-
synonymous/synonymous ratios for GLRA4 from Exac are marked as
”Exac”. The darker colors show the values for common variants and the
lighter shades show the values for rare variants. GLRA4 does not have the











acional de Investigaciones C
ardiovasculares user on 29 O
ctober 2018
7082 Nucleic Acids Research, 2018, Vol. 46, No. 14
the nine proteins) and are therefore erroneously annotated
as coding. This in turn suggests that the novel sequences in
CHESS predicted as coding because of their similarity to
the nine proteins (more than half of the novel coding genes
in CHESS) will also be transposon-related.
Clearly, misannotating genes as protein coding can have
important downstream effects on a wide range of databases
that depend on reliable predictions of coding genes. The
CHESS database’s prediction of hundreds of new coding
genes based on a defunct, transposon-linked Pfam domain
underscores how easily misclassifications can proliferate.
A number of other dead Pfam domains may have been
used to help validate the potential non-coding genes, for ex-
ample C19orf48 and C1orf145. We also ran the Pfam-based
tool Antifam (52) to check whether any genes had similar-
ity to known non-coding domains and we found evidence
for two more genes, AC079355.1 and AC118758.1, which
mapped to the same ‘spurious ORF’ domain. Both coding
genes are automatic predictions.
DISCUSSION
There are >22 000 genes annotated as coding across
the Ensembl/GENCODE, RefSeq and UniProtKB human
proteomes. While manual annotators agree on >19 000
genes, one in eight of these genes are classified differently
in at least one of the reference sets. Evidence from various
sources suggests that many of the genes classified differently
across the three reference sets are unlikely to code for es-
sential proteins; these genes have poor UniProtKB evidence
scores, a higher proportion of the most damaging germline
variants and non-synonymous to synonymous substitution
ratios that suggest many are under neutral selection.
To study differences between these genes and genes
annotated as coding in all three reference sets we de-
fined a set of 16 potential non-coding features from the
Ensembl/GENCODE reference set. More than 11% of
Ensembl/GENCODE coding genes had at least one poten-
tial non-coding feature and there were profound differences
between these genes and the remaining 89% of genes. Only
a handful of potential non-coding genes had reliable pro-
teomics or antibody evidence, most had significantly lower
transcript expression and their transcripts were detected in
very few tissues. Non-coding genes are known to have much
lower levels of expression than coding genes (53), so the fact
that so many potential non-coding genes had low or negli-
gible RNAseq expression levels supports the possibility that
many will not code for proteins.
Data from genetic variation studies showed that potential
non-coding genes had many more copy number variants,
a much higher rate of potentially damaging variants, and
larger non-synonymous to synonymous substitution ratios.
The pattern of variants suggested that many of these genes
are under neutral selection. Since neutral selection is not
typical of coding genes, this reinforces the likelihood that
many potential non-coding genes will not code for func-
tional proteins.
There are 4234 coding genes that could be considered po-
tentially non-coding across the three reference sets. These
genes are either annotated differently across the three refer-
ence sets or were flagged as potential non-coding (Supple-
mentary Figure S4). If the majority do not code for proteins,
as the genetic variation patterns suggest, the number of cod-
ing genes will be much closer to the 19 446 genes common
to the three reference sets than to the 22 210 genes in the
union of those sets. However, it is still early to speculate on
the precise number of coding genes because it is impossi-
ble to know how many potential non-coding genes will be
reclassified by manual annotators, and because there is a
steady trickle of new coding genes being annotated (54).
Human population variation data shows that two types
of genes in particular appeared not under selection pressure
and were therefore unlikely to code for functional proteins.
The first are automatic gene predictions, genes in which all
gene models are predicted, which make up approximately
1% of Ensembl/GENCODE coding genes and more than
4% of RefSeq coding genes. Our results suggest that these
genes are adding little to the human reference annotation.
The second group of genes are likely pseudogenes. Pseudo-
genes form the largest group of non-coding annotations and
are especially difficult to distinguish from coding genes but
have the clearest evidence for neutral selection of all the po-
tential non-coding features. Likely pseudogenes are partic-
ularly prevalent in the UniProtKB unique subset.
Pseudogenes highlight the difficulties that manual anno-
tators face when interpreting the available data (55). Most
pseudogenes derive from protein coding genes, either by
duplication or retrotransposition, and as a result often
have large intact ORFs and protein-like features. In addi-
tion recent duplications usually have few obviously delete-
rious mutations, making the distinction between coding and
pseudogene even more difficult. The Ubiquitin carboxyl-
terminal hydrolase 17 family has 26 close to identical mem-
bers, but while non-synonymous to synonymous ratios sug-
gest that most or all are pseudogenes, they are all annotated
as coding because there is no clear way of discriminating be-
tween them.
Experimental evidence is often ambiguous for many
pseudogenes. Negative evidence (evidence to show that a
gene does not code for proteins) does not exist, antibod-
ies are rarely sufficiently specific to distinguish similar pro-
teins and proteomics experiments can easily confuse sim-
ilar peptides because of single-amino acid variations or
post-translational modifications. Indeed, a number of the
potential non-coding genes detected in the proteomics ex-
periments may be false positive identifications. For exam-
ple PeptideAtlas validates two peptides for potential non-
coding gene FO538757.2. The two peptides identified for
FO538757.2 are just one amino acid different from the
equivalent peptides from WASH1, a likely coding gene. In-
deed UniProtKB annotates both these single amino acid
differences as known WASH1 sequence conflicts. It is more
than probable that the peptides we detected for FO538757.2
really came from WASH1. Here we should point out that
although some identifications will be false positives, many
potential non-coding genes, such as SEMG1 and SEMG2,
sperm-specific potential non-coding genes with a primate
origin, were identified with strong peptide evidence.
The increase in genetic variation data (42,51) should pro-
vide valuable support for manual annotators in this sense,
though genetic diversity is not infinite and it will not be
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have very few high impact variants in common alleles and
should have non-synonymous to synonymous ratios that
are lower for common allele than they are for rare alleles.
We have used genetic variation data to flag a number of
possible pseudogenes that were not caught by our potential
non-coding features (for example PLK5, GLRA4).
Over the years since the human genome sequence was re-
leased (4) rigorous manual annotation has brought us con-
siderably closer to a final catalogue of human coding genes
and annotators agree for more than 85% of coding genes.
The final 12% of genes, those with the most conflicting evi-
dence, will be more difficult to classify. One useful source of
information to discriminate coding from non-coding genes
makes use of the recent increase in the number of annotated
mammalian genomes (27). With time and with more exten-
sive data, large-scale genetic variation studies could also be
a powerful tool to aid in the annotation of coding genes.
In order to flag potential non-coding genes we have built
a pipeline that updates with the Ensembl/GENCODE ref-
erence set. This approach is a highly practical means of in-
forming the curation of the human genome. The set of hu-
man coding genes needs to be as complete as possible for
biomedical experiments, but inevitably some genes will be
misannotated as coding. Once a gene has entered a refer-
ence set it may be propagated in large-scale databases and
its coding potential may end up being validated via circular
annotation. Detecting errors, retracing steps and rescinding
the coding status of a gene once it is annotated as coding
is a difficult process, so a system to catch and label genes
that have conflicting or insufficient coding support is use-
ful. The pipeline will be used to help pinpoint potential non-
coding genes in the Ensembl/GENCODE human reference
set. However, the approach could be made available for use
by other annotation initiatives and could be extended to the
annotation of other species. In fact, a pipeline has already
been developed for the mouse reference set. Future releases
of these analyses will be made publicly available.
Manual curators from the three main reference databases
will investigate and debate the coding potential of these po-
tential non-coding genes. It is important to note that while
many potential non-coding genes will be reclassified, those
that have evidence of coding capability will be maintained
in the reference set. In addition a number of genes with con-
flicting evidence or insufficient evidence to determine cod-
ing status one way or another are also likely to be remain
in the reference set. It may be possible to flag this second
set of genes as potentially non-coding or pseudogene, while
maintaining them as coding in the reference set.
Even if just half of these the potential non-coding genes
we have highlighted turn out to be non-coding, this would
clearly have a substantial impact on a range of fields. In
particular, overestimating the number of coding genes in-
evitably complicates large-scale biomedical experiments, es-
pecially those that involve the mapping of disease-related
variations to human genes. The more potential non-coding
genes that are classified as coding as part of any analytical
process, the noisier the results.
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